Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5448MR)

This product GTTS-WQ5448MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5448MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8281MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ13039MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ13986MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ11321MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ10053MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ15513MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ5391MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ1989MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW